According to a study from the United States, "Several studies have examined serum creatinine as a marker for prostate cancer stage, recurrence, and prognosis. We evaluated whether serum creatinine concentration was associated with risk of developing prostate cancer in a prospective cohort of male smokers."
"A nested case-control study within the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study of 50- to 69-year-old Finnish men was conducted. Two controls (n = 464) were matched to each case (n = 232) on study center, intervention group, date of baseline blood draw (+/- 45 days), and age (+/- 5 years). Conditional logistic regression was used to calculate odds ratios and 95% confidence intervals. All P values were two-sided. Cases had significantly higher prediagnostic serum creatinine concentrations compared with controls (medians of 1.13 versus 1.10 mg/dL, respectively; P = 0.004). Serum creatinine was associated with a significantly greater risk of prostate cancer (multivariate odds ratio, 2.23; 95% confidence interval, 1.33-3.75 for highest versus lowest quartile), with a significant trend (P trend = 0.0008). Exclusion of subjects with a reported history of diabetes, benign prostatic hyperplasia, or hypertension, or whose cancer was diagnosed within the first 5 years of follow-up, did not alter the association. Risk did not differ by disease stage or time from blood draw to diagnosis. Prospectively measured serum creatinine, within normal ranges, is positively related to prostate cancer risk," wrote S.J. Weinstein and colleagues, National Institutes of Health (see also Prostate Cancer).
The researchers concluded: "Future research should reexamine the association in other populations, including any interrelationship with serum prostate-specific antigen. (Cancer Epidemiol Biomarkers Prev 2009;18(10):2643-9)."
Weinstein and colleagues published the results of their research in Cancer Epidemiology Biomarkers & Prevention (Serum Creatinine and Prostate Cancer Risk in a Prospective Study. Cancer Epidemiology Biomarkers & Prevention, 2009;18(10):2643-2649).
For additional information, contact S.J. Weinstein, National Cancer Institute, Nutrition Epidemiology Branch, DCEG, National Institutes of Health, DHHS, 6120 Execut Blvd., Suite 320, Bethesda, MD 20892, USA.
The publisher of the journal Cancer Epidemiology Biomarkers & Prevention can be contacted at: American Association Cancer Research, 615 Chestnut St., 17TH Floor, Philadelphia, PA 19106-4404, USA.
Keywords: City:Bethesda, State:MD, Country:United States, Cancer Epidemiology, Clinical Trial Research, Oncology, Prostate Cancer, Prostatic Neoplasms, Recurrence, National Institutes of Health.
This article was prepared by Disease Risk Factor Week editors from staff and other reports. Copyright 2009, Disease Risk Factor Week via NewsRx.com.
To see more of the NewsRx.com, or to subscribe, go to http://www.newsrx.com .